SEC Filing Summary: Tharimmune, Inc. (THAR)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Tharimmune, Inc. on April 28, 2025. The registrant is a Delaware corporation with its principal executive offices in Bridgewater, NJ, and its common stock trades on The Nasdaq Stock Market LLC under the symbol "THAR." The company is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
On April 28, 2025, the Board of Directors increased the size of the Board from its previous count to nine members. The Board appointed Clay Kahler and Gary Stetz as new directors.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of the director appointments under Item 5.02.
Investor Verification Checklist
- Verify the professional backgrounds and potential conflicts of interest for new directors Clay Kahler and Gary Stetz.
- Confirm the total number of board seats and the composition of board committees following the expansion to nine members.
- Review the company's most recent 10-K or 10-Q filings for the latest financial metrics, as this 8-K does not contain them.